Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 359

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 359
---
LS acquired full global development and commercialization rights to Aexon’s Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin -1and orexin -2receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro -degenerativedisorders such as Parkinson’s and Alzheimer’s disease. This license agreement represents a potentially leading next -generation, first -in-class, oral, dual orexin receptor agonist platform that is expected to address high unmet medical needs and has shown promising results in pre -clinicalin vitro assays. NLSP has plans to initiate proof -of-conceptpreclinical development following the Merger, subject to sufficient funding. The possibility to acquire this novel and unique platform, consisting of over 300 compounds, bridges the present to the future treatment of sleep disorders as well as other neuro -degenerativedisorders. Orexin receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological processes of neurological diseases such as obesity, narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer’s disease. These new compounds, in addition to NLS’s current pipeline, including Mazindol ER for the treatment of narcolepsy, NLS -4focused on idiopathic hypersomnia, long -COVIDand chronic fatigue syndrome, and NLS -11, addressing Kleine -LevinSyndrome and neurodegenerative diseases, will further complement and strengthen NLS’s sleep franchise. NLS will be uniquely positioned to hold the key to unlock the challenges associated with rare sleep disorders now and in the future. 188 In addition, NLS initiated a comprehensive exploration of new opportunities that align with NLS’s core values and strengths, with the goal of diversifying NLS’s revenue streams, mitigating risks and creating lasting value for NLS’s stakeholders. As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including strategic partnerships, out licensing assets of the Company, and other future strategic actions. Several strategic partnerships discussions are currently under way and in advanced stages of negotiations. As always, NLS continued to approach the sleep medicine market from a holistic perspective. According to Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments —